Shouping Xu Selected Research

Triple Negative Breast Neoplasms

1/2023	A machine learning model to predict efficacy of neoadjuvant therapy in breast cancer based on dynamic changes in systemic immunity.
1/2021	Quantification of Ki67 Change as a Valid Prognostic Indicator of Luminal B Type Breast Cancer After Neoadjuvant Therapy.
1/2021	Hypoxia-Mediated Complement 1q Binding Protein Regulates Metastasis and Chemoresistance in Triple-Negative Breast Cancer and Modulates the PKC-NF-κB-VCAM-1 Signaling Pathway.
10/2016	Novel cell-penetrating peptide-loaded nanobubbles synergized with ultrasound irradiation enhance EGFR siRNA delivery for triple negative Breast cancer therapy.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shouping Xu Research Topics

Disease

46	Neoplasms (Cancer) 03/2024 - 01/2010
31	Breast Neoplasms (Breast Cancer) 04/2023 - 11/2012
4	Triple Negative Breast Neoplasms 01/2023 - 10/2016
4	Head and Neck Neoplasms (Head and Neck Cancer) 01/2023 - 09/2010
4	Neoplasm Metastasis (Metastasis) 04/2022 - 01/2021
3	Carcinogenesis 02/2022 - 12/2019
2	Squamous Cell Carcinoma of Head and Neck 01/2021 - 04/2015
2	Hypoxia (Hypoxemia) 01/2021 - 01/2018
2	Nasopharyngeal Carcinoma 01/2021 - 05/2013
2	Lung Neoplasms (Lung Cancer) 01/2020 - 01/2018
2	Nasopharyngeal Neoplasms (Cancer of the Nasopharynx) 06/2016 - 09/2012
2	Endometrial Neoplasms (Endometrial Cancer) 11/2013 - 01/2010
1	Weight Loss (Weight Reduction) 07/2023
1	Genomic Instability 01/2021
1	Xerostomia 01/2021
1	Radiation Pneumonitis 01/2020
1	Non-alcoholic Fatty Liver Disease 01/2020

Drug/Important Bio-Agent (IBA)

14	Long Noncoding RNAIBA 02/2023 - 01/2015
7	RNA (Ribonucleic Acid)IBA 01/2021 - 01/2017
6	Proteins (Proteins, Gene)FDA Link 02/2022 - 10/2016
4	Biomarkers (Surrogate Marker)IBA 02/2022 - 10/2016
4	Messenger RNA (mRNA)IBA 11/2021 - 10/2016
3	Therapeutic UsesIBA 01/2023 - 06/2014
3	6-methyladenineIBA 01/2022 - 01/2021
3	N-methyladenosineIBA 01/2022 - 01/2021
3	Phenobarbital (Luminal)FDA Link 11/2021 - 01/2017
3	Competitive Endogenous RNAIBA 08/2021 - 01/2020
3	Paclitaxel (Taxol)FDA LinkGeneric 01/2021 - 01/2018
3	hydrogen sulfite (bisulfite)IBA 01/2021 - 01/2018
2	AntigensIBA 03/2024 - 01/2022
2	ErbB Receptors (EGF Receptor)IBA 04/2023 - 10/2016
2	N-acetyltalosaminuronic acid (NAT)IBA 04/2023 - 01/2023
2	Immune Checkpoint InhibitorsIBA 01/2023 - 01/2022
2	IronIBA 01/2022 - 01/2019
2	Hormones (Hormone)IBA 01/2022 - 11/2012
2	Phospholipid Hydroperoxide Glutathione PeroxidaseIBA 01/2022 - 01/2020
2	Estrogen ReceptorsIBA 01/2022 - 12/2017
2	Indicators and Reagents (Reagents)IBA 11/2021 - 01/2021
2	Cell-Free Nucleic AcidsIBA 08/2021 - 01/2021
2	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2017
2	ChromatinIBA 01/2021 - 10/2019
2	trans-crotonin (CTN)IBA 06/2016 - 04/2015
1	Neoplasm Antigens (Tumor Antigens)IBA 03/2024
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 03/2024
1	CytokinesIBA 09/2023
1	Epinephrine (Adrenaline)FDA LinkGeneric 09/2023
1	Untranslated RNA (Noncoding RNA)IBA 01/2023
1	B7-H1 AntigenIBA 01/2023
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 04/2022
1	UbiquinoneIBA 01/2022
1	Glutathione (Reduced Glutathione)IBA 01/2022
1	Lipoxygenase (Lipoxygenase-1)IBA 01/2022
1	human ERBB2 proteinIBA 01/2022
1	Progesterone Receptors (Progesterone Receptor)IBA 01/2022
1	Superoxides (Superoxide)IBA 01/2022
1	Class E Scavenger Receptors (Lectin Like Oxidized Low Density Lipoprotein Receptor 1)IBA 12/2021
1	oxidized low density lipoproteinIBA 12/2021
1	Free RadicalsIBA 10/2021
1	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2021
1	ferrous sulfideIBA 10/2021
1	Transcription Factors (Transcription Factor)IBA 08/2021
1	Small Nucleolar RNA (snoRNA)IBA 08/2021
1	Complement C1q (C1q Complement)IBA 01/2021
1	Transfer RNA (tRNA)IBA 01/2021
1	NF-kappa B (NF-kB)IBA 01/2021
1	Ribonucleases (Ribonuclease)IBA 01/2021
1	Protein Kinase CIBA 01/2021
1	LigandsIBA 01/2021
1	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)IBA 01/2021
1	Ephrin-A4 (Ephrin A4)IBA 01/2021
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2021
1	Carrier Proteins (Binding Protein)IBA 01/2021
1	Mitochondrial Proteins (Mitochondrial Protein)IBA 01/2020
1	histone H3 trimethyl Lys4IBA 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	Immune Checkpoint ProteinsIBA 01/2020
1	Miat long non-coding RNAIBA 01/2020
1	Complement System Proteins (Complement)IBA 12/2019
1	LuciferasesIBA 10/2019
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2019
1	Transcription Factor AP-2IBA 01/2019
1	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2018
1	Cyclin D1IBA 12/2017
1	CateninsIBA 12/2017
1	bis(2,4-dinitrophenyl)carbonateIBA 07/2017
1	Histones (Histone)IBA 01/2017
1	6-chloro-2-(1-piperazinyl)pyrazine (CPP)IBA 10/2016

Therapy/Procedure

15	Therapeutics 12/2023 - 11/2012
14	Radiotherapy 09/2021 - 01/2010
9	Intensity-Modulated Radiotherapy (Radiotherapy, Intensity Modulated) 07/2023 - 01/2010
6	Immunotherapy 01/2023 - 01/2020
5	Neoadjuvant Therapy 04/2023 - 01/2021
2	Drug Therapy (Chemotherapy) 10/2021 - 09/2021
1	Lymph Node Excision (Lymph Node Dissection) 01/2022
1	Operative Surgical Procedures 01/2022
1	Lasers (Laser) 10/2021
1	Intravenous Injections 10/2021
1	Oncolytic Virotherapy 09/2021
1	Biological Therapy 09/2021
1	Induction Chemotherapy 01/2021